CN1422153A - 采用心动徐缓剂治疗肥大型心肌疾病及新颖药品组合物 - Google Patents
采用心动徐缓剂治疗肥大型心肌疾病及新颖药品组合物 Download PDFInfo
- Publication number
- CN1422153A CN1422153A CN01807959A CN01807959A CN1422153A CN 1422153 A CN1422153 A CN 1422153A CN 01807959 A CN01807959 A CN 01807959A CN 01807959 A CN01807959 A CN 01807959A CN 1422153 A CN1422153 A CN 1422153A
- Authority
- CN
- China
- Prior art keywords
- pyridine
- bradley
- treatment
- channel blocker
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031229 Cardiomyopathies Diseases 0.000 title claims abstract description 5
- 206010020880 Hypertrophy Diseases 0.000 title abstract description 4
- 239000000126 substance Substances 0.000 title abstract description 4
- 230000000059 bradycardiac effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims abstract description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 70
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 35
- 239000000463 material Substances 0.000 claims description 18
- 230000036471 bradycardia Effects 0.000 claims description 15
- 208000006218 bradycardia Diseases 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 3
- KEDQCFRVSHYKLR-UHFFFAOYSA-N 3-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCN1C(=O)CC2=CC(OC)=C(OC)C=C2CC1 KEDQCFRVSHYKLR-UHFFFAOYSA-N 0.000 claims description 2
- OBUFMJDDZTXJPY-NRFANRHFSA-N 3-[[(3s)-1-[2-(3,4-dimethoxyphenyl)ethyl]piperidin-3-yl]methyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Chemical compound C1=C(OC)C(OC)=CC=C1CCN1C[C@@H](CN2C(CC3=CC(OC)=C(OC)C=C3CC2)=O)CCC1 OBUFMJDDZTXJPY-NRFANRHFSA-N 0.000 claims description 2
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 229950010208 cilobradine Drugs 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 150000008131 glucosides Chemical class 0.000 claims description 2
- 239000003087 receptor blocking agent Substances 0.000 claims description 2
- 229950003419 zatebradine Drugs 0.000 claims description 2
- 230000024883 vasodilation Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 2
- 239000002876 beta blocker Substances 0.000 abstract 1
- 239000000496 cardiotonic agent Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229920002261 Corn starch Polymers 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000008120 corn starch Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000010410 dusting Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 239000007940 sugar coated tablet Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229960003746 metildigoxin Drugs 0.000 description 2
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- -1 liquor Substances 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种心动徐缓物质，例如Ca++通道阻断剂、β－受体阻断剂或if通道阻断剂的新用途，if通道阻断剂是优选的，与用于心脏的物质任意混合，降低肥大型心肌病的退化，特别是用于人和家养动物原发性的肥大型心肌病的治疗。
Description
采用心动徐缓物质可以治疗上升的心率，特别是Ca++通道阻断剂例如地尔硫卓和维拉帕米，或β-受体阻断剂例如阿替洛尔、比索洛尔、卡维洛尔、美多洛尔或心得安，以及if通道阻断剂例如查特布拉啶(zatebradine)[1-(7，8-二甲氧基-1，3，4，5-四氢-2H-3-苯基氮杂-2-酮-3-基)-3-[N-甲基-N-(2-(3，4-二甲氧基-苯基)-乙基)丙烷](参阅EP-B-0 065 229)，3-[(N-(2-(3，4-二甲氧基-苯基)-乙基)-哌啶-3-基)-甲基]-(7，8-二甲氧基-1，3，4，5-四氢-2H-3-苯基氮杂-2-酮)(参阅EP-B-0 224 794)及其对映体西洛布拉啶(cilobradine)[(+)-3-[(N-(2-(3，4-二甲氧基-苯基)-乙基)-哌啶-3-(S)-基)-甲基](7，8-二甲氧基-1，3，4，5-四氢-2H-3-苯基氮杂-2-酮]或者烯丙尼啶[2-(N-烯丙基-2，6-二氯苯胺基)-2-咪唑烷，也可参阅美国专利No.3,708,485]，而且，还知道查特布拉啶对治疗心的机能不全也有适当的效果(参阅EP-B-0 471 388)。
然而，还已知该心动徐缓物质，特别是上述化合物，其中if通道阻断剂例如查特布拉啶、西洛布拉啶或烯丙尼啶，其中，西洛布拉啶是特别优选的，对于肥大型心肌疾病的症状治疗有利，特别适于原发性肥大型心肌病(HCM)例如心肌梗塞后心肌残留肥大、缺血性心肌病、瓣膜缺损的心肌肥大以及毒性或医源性影响的心肌肥大的治疗。
目前，惊奇地发现，心动徐缓物质，其中if通道阻断剂例如查特布拉啶、西洛布拉啶或烯丙尼啶，特别是西洛布拉啶是优选的，它不仅对肥大型心肌病的临床症状有适当的治疗效果，而且，甚至导致这些严重心脏病的消退。
本发明涉及心动徐缓物质，特别是上述化合物的一种新的用途，其中，if通道阻断剂例如查特布拉啶、西洛布拉啶或烯丙尼啶，特别是西洛布拉啶是优选的，它们导致肥大型心肌病的消退，特别适于人类和家养动物的原发性肥大型心肌病的治疗。
为了达到本发明的上述效果，采用文献中对单个心动徐缓物质用于治疗提高心率所给出的剂量的心动徐缓物质是适宜的。例如，西洛布拉啶的一次剂量，口服为0.1至0.5mg/kg，优选是0.2至0.4mg/kg、每天1至3次，对查特布拉啶是0.2至1mg/kg、每天2次，对烯丙尼啶是0.5至5mg/kg、每天2次。
本发明心动徐缓物质的新用途，是采用if通道阻断剂-西洛布拉啶作为实施例的方法进行研究，采用下列方法：
得了严重肥大型心肌病(心率约200次/分钟)的猫，采用ST增强的心电图作为心肌缺血信号，在血中以及在超声图像中肌酸激酶活性的增加，随着心室容积和痰分的减少心室壁的巨大压缩表明，在用if通道阻断剂例如西洛布拉啶(0.3mg/kg口服，每天2次)治疗后，临床症状有很大的改进(痛苦消除，心电图正常，正常的生理活性图像恢复)。
在1年以及大约2年治疗后，研究惊人地表明心肌的肥大消退，并保持症状改善。
以猫的肥大型心肌病作为模型对人体相应疾病进行研究(Kittleson等人，Circulation 91，3172-3180(1999))。
用if通道阻断剂西洛布拉啶不仅导致症状改善，而且疾病消退。
本发明还涉及药物组合物，其中含有至少一种心动徐缓物质，特别是一种上述化合物，优选是if通道阻断剂，和至少一种作用于心脏的物质，例如心糖苷如甲基地高辛或洋地黄毒苷；血管舒扩张剂如硝酸甘油；ACE抑制剂如卡托普利或依那普利；血管紧张素-II拮抗剂如洛沙丹(losartan)或替蜜沙丹(telmisartan)，该组合物对于肥大型心肌病的治疗也是适合的，特别适于原发性肥大型心肌病(HCM)的治疗，通过将它们与心动徐缓物质组合，可以防止心率上升。
为了达到本发明的效果，一般使用由文献中已知的单一的心动徐缓物质用于治疗心率上升的剂量，以及文献中已知的作用于心脏物质所用的剂量。
为了这个目的，心动徐缓物质，既可独立地用它们，也可与其他的作用于心脏的化合物组合使用，与一种或多种常用的惰性载体及/或稀释剂，例如与玉米淀粉、乳糖、葡萄糖、微晶纤维素、硬脂酸镁、聚乙烯基吡咯烷酮、柠檬酸、酒石酸、水、水/乙醇、水/丙三醇、水/山梨醇、水/聚乙二醇、丙二醇、硬脂醇、羧甲基纤维素或脂类物质例如硬脂防或其适当的混合物配制，以制成常用的药物制剂例如普通片剂、糖衣片剂、胶囊、粉剂、悬浮剂、液剂、喷雾剂或栓剂。
因此，例如，由西洛布拉啶和作用于心脏的化合物形成的组合物，一般每次口服含有0.1至0.5mg/kg，优选0.2至0.4mg/kg的西洛布拉啶，加上0.01至1mg的甲基地高辛，每天1至2次；0.01至1mg地高辛，每天1次；0.1至2mg的硝酸甘油，每天2至3次；10至100mg的卡托普利，每天1至2次；2至20mg的依那普利，每天1次；10至200mg的洛沙丹，每天2次；或20至80mg的替蜜沙丹，每天1次。
作为在药物组合物中if通道阻断剂的配偶体另外作用在单独的生物体系，并且，if通道阻断剂抑制心率的反射增加，它在与上述混合配偶体组合时可能产生，这些具有协同效应。
通过下列实施例说明本发明，但本发明不受其局限。
实施例1含有1.25mg西洛布拉啶的胶囊组成：1胶囊含有：
乳糖一水合物 82.75mg
玉米淀粉 55.3mg制造方法
把活性物质、乳糖一水合物和玉米淀粉加以混合，填充至4号胶囊中。
实施例2含10mg西洛布拉啶的胶囊。组成：1胶囊含有：
乳糖一水合物 77.6mg
玉米淀粉 51.7mg制造方法
把活性物质、乳糖一水合物和玉米淀粉加以混合，填充至4号胶囊中。
实施例3
含7.5mg西洛布拉啶的片剂组成：1片剂含有：
活性物质 7.5mg
玉米淀粉 59.5mg
乳糖 48.0mg
聚乙烯吡咯烷酮 4.0mg
硬脂酸镁 1.0mg
合计 120.0mg制造方法
把活性物质、玉米淀粉、乳糖和聚乙烯吡咯烷酮进行混合，用水湿润。对湿润的混合物迫使通过1.5目细筛，并于45℃干燥。使干燥的颗粒通过1.0目细筛并与硬脂酸镁混合。把最终的混合物用配有分开槽的7mm直径的冲模的压片机压制成片剂，形成片。
每片重量：120mg
实施例4含5mg西洛布拉啶的糖衣片剂1片剂芯含有：
活性物质 5.0mg
玉米淀粉 41.5mg
乳糖 30.0mg
聚乙烯吡咯烷酮 3.0mg
硬脂酸镁 0.5mg
合计 80.0mg制造方法
把活性物质、玉米淀粉、乳糖和聚乙烯吡咯烷酮均匀混合，用水湿润。对湿润的物质迫使通过1.0mm细筛并于45℃干燥，然后，使颗粒物通过同样的细筛。在与硬脂酸镁混合后，用压片机压制成直径6mm的凸状片芯。把这样制成的片芯，用己知的方法，用含有主要是蔗糖和滑石的涂层液进行涂布。用蜡抛光最终的糖衣片剂。
糖衣片剂重量：130mg
实施例5含5mg西洛布拉啶的安瓿1安瓿含有：
活性物质 5.0mg
山梨醇 50.0mg
注射用水 2.0mg制造方法
在适当的混合容器内使活性物质溶于注射用水中，用山梨醇使该溶液等渗。
通过膜式过滤器过滤后，在氮气氛中把溶液注入经过洗涤和灭菌的安瓿中，并且在水蒸汽汽流中高压灭菌20分钟。
实施例6含10mg西洛布拉啶的栓剂1栓剂含有：
活性物质 0.010g
硬脂肪(例如，Witepsol H19和W45) 1.690g
合计 1.700g制造方法
把硬脂肪熔融。于38℃，把碾碎的活性物质均匀分散在熔融物中。冷却至35℃，注入稍为冷却的栓剂模中。
实施例7含10mg西洛布拉啶的滴剂100ml溶液中含有：
活性物质 0.2g
羟乙基纤维素 0.15g
酒石酸 0.1g
山梨醇溶液，70％干重 30.0g
丙三醇 10.0g
苯甲酸 0.15g
蒸馏水 加至100ml制造方法
把蒸馏水加热至70℃。在搅拌下把羟乙基纤维素、苯甲酸和酒石酸溶于其中。把溶液冷却至室温，在搅拌下添加丙三醇和山梨醇溶液。在室温下添加活性物质，搅拌该混合物使完全溶解。然后，搅拌下抽真空以从糖浆中除去空气。
Claims (8)
1.一种用于治疗肥大型心肌疾病的药物组合物，其中含有心动徐缓物质和任意的作用于心脏的物质。
2.按照权利要求1的药物组合物，其特征是，用Ca++通道阻断剂、β-受体阻断剂或if通道阻断剂作为心动徐缓物质。
3.按照权利要求1的药物组合物，其特征是，使用if通道阻断剂作为心动徐缓物质。
4.按照权利要求3的药物组合物，其特征是，使用查特布拉啶(zatebradine)、西洛布拉啶(cilobradine)或烯丙尼啶作为if通道阻断剂。
5.按照权利要求3的药物组合物，其特征是，使用西洛布拉啶作为if通道阻断剂。
6.按照权利要求1至5的药物组合物，其特征是，它们还含有作为另一种作用于心脏的化合物的心糖苷、血管舒张剂、ACE-抑制剂或血管紧张素-II拮抗物。
7.使用权利要求1至6中所述的活性物质，治疗肥大型心肌病。
8.使用权利要求1至6中所述的活性物质制备药物组合物，以用于治疗肥大型心肌病。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10018401.4 | 2000-04-13 | ||
| DE10018401A DE10018401A1 (de) | 2000-04-13 | 2000-04-13 | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1422153A true CN1422153A (zh) | 2003-06-04 |
| CN1245963C CN1245963C (zh) | 2006-03-22 |
Family
ID=7638652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB018079598A Expired - Fee Related CN1245963C (zh) | 2000-04-13 | 2001-04-07 | 包括心动徐缓剂的药物组合物及其用途 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7208508B2 (zh) |
| EP (2) | EP1276476B1 (zh) |
| JP (1) | JP3905386B2 (zh) |
| KR (1) | KR20020089453A (zh) |
| CN (1) | CN1245963C (zh) |
| AT (1) | ATE330588T1 (zh) |
| AU (2) | AU2001270484B2 (zh) |
| BG (1) | BG65816B1 (zh) |
| BR (1) | BR0109996A (zh) |
| CA (2) | CA2575059A1 (zh) |
| CY (1) | CY1105081T1 (zh) |
| CZ (1) | CZ300549B6 (zh) |
| DE (2) | DE10018401A1 (zh) |
| DK (1) | DK1276476T3 (zh) |
| EA (1) | EA006977B1 (zh) |
| EE (1) | EE05099B1 (zh) |
| ES (1) | ES2266216T3 (zh) |
| HR (1) | HRP20020815A2 (zh) |
| HU (1) | HU228387B1 (zh) |
| IL (2) | IL152103A0 (zh) |
| ME (1) | MEP45908A (zh) |
| MX (1) | MXPA02009935A (zh) |
| NO (1) | NO330311B1 (zh) |
| NZ (1) | NZ521934A (zh) |
| PL (1) | PL215235B1 (zh) |
| PT (1) | PT1276476E (zh) |
| RS (1) | RS51478B (zh) |
| SI (1) | SI1276476T1 (zh) |
| SK (1) | SK286075B6 (zh) |
| TR (1) | TR200202326T2 (zh) |
| UA (1) | UA78679C2 (zh) |
| WO (1) | WO2001078699A2 (zh) |
| ZA (1) | ZA200208162B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015557B (zh) * | 2005-12-21 | 2010-12-08 | 瑟维尔实验室 | 窦房结If电流抑制剂与血管紧张肽转化酶抑制剂的新组合以及含有它的药物组合物 |
| CN102284060A (zh) * | 2010-06-15 | 2011-12-21 | 瑟维尔实验室 | 窦房结If当前抑制剂和血管紧张素转化酶抑制剂的组合在治疗心力衰竭中的用途 |
| TWI415605B (zh) * | 2006-10-06 | 2013-11-21 | 百靈佳殷格翰維美迪加股份有限公司 | 用於預防或治療貓之全身性疾病之血管緊張素ii受體拮抗劑 |
| CN103781468A (zh) * | 2011-08-12 | 2014-05-07 | 勃林格殷格翰动物保健有限公司 | 治疗及预防猫科动物心脏衰竭的方法中所用的起搏电流(If)抑制剂 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| US20040138306A1 (en) * | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| PT1362590E (pt) * | 2002-07-25 | 2004-05-31 | Boehringer Ingelheim Pharma | Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca |
| JP3874419B2 (ja) * | 2003-01-31 | 2007-01-31 | 三共株式会社 | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
| EP1898951B1 (en) * | 2005-06-27 | 2013-02-27 | Daiichi Sankyo Company, Limited | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
| CA2617519A1 (en) * | 2005-08-23 | 2007-03-01 | Astellas Pharma Inc. | Agent for treating atrial fibrillation |
| EP1762179A1 (en) | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Method for improving diagnostic quality in echocardiography |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| ES2598490T3 (es) | 2009-05-20 | 2017-01-27 | Boehringer Ingelheim Vetmedica Gmbh | Disolución farmacéutica bebible de telmisartán |
| KR101296743B1 (ko) * | 2011-02-17 | 2013-08-20 | 한국과학기술연구원 | 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법 |
| EP2953612A1 (en) | 2013-02-11 | 2015-12-16 | Boehringer Ingelheim Vetmedica GmbH | Kit-of-parts |
| DK3648761T3 (da) | 2017-07-07 | 2024-06-24 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan til forebyggelsen eller behandlingen af hypertension i katte |
| KR102398532B1 (ko) | 2020-07-20 | 2022-05-13 | 한림대학교 산학협력단 | 중증 지주막하출혈 진단용 조성물 |
| KR102331806B1 (ko) | 2020-07-20 | 2021-12-01 | 한림대학교 산학협력단 | 중증 지주막하출혈 진단용 바이오 마커 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759125A (fr) | 1969-11-19 | 1971-05-18 | Boehringer Sohn Ingelheim | Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer |
| DE3119874A1 (de) | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| DE3541811A1 (de) * | 1985-11-27 | 1987-06-04 | Thomae Gmbh Dr K | Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5175157A (en) * | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
| DE3736866A1 (de) * | 1987-10-30 | 1989-05-11 | Thomae Gmbh Dr K | Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz |
| DE3805635A1 (de) | 1988-02-24 | 1989-09-07 | Thomae Gmbh Dr K | Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica |
| US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
| RU2078536C1 (ru) * | 1993-09-02 | 1997-05-10 | Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско | Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией |
| BR9407613A (pt) * | 1993-09-24 | 1997-01-14 | Procter & Gamble | Novos compostos deoxi e 14-amino esteróide contendo açúcar substituído com oxigênio |
| US5595987A (en) * | 1994-07-22 | 1997-01-21 | The Trustees Of Columbia University In The City Of New York | Method of slowing ventricular arrhythmias using zatebradine |
| US6083991A (en) * | 1997-06-04 | 2000-07-04 | University Of Florida Research Foundation, Inc. | Anti-arrhythmic composition and methods of treatment |
| DE19741635A1 (de) * | 1997-09-22 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| CN1234357C (zh) * | 1998-07-10 | 2006-01-04 | 诺瓦提斯公司 | 缬沙坦和钙通道阻断剂的抗超敏组合 |
| DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| CA2435526A1 (en) | 2002-07-25 | 2004-01-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| US20040138306A1 (en) * | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| EP1762179A1 (en) * | 2005-09-07 | 2007-03-14 | Boehringer Ingelheim Vetmedica Gmbh | Method for improving diagnostic quality in echocardiography |
-
2000
- 2000-04-13 DE DE10018401A patent/DE10018401A1/de not_active Withdrawn
-
2001
- 2001-04-07 IL IL15210301A patent/IL152103A0/xx unknown
- 2001-04-07 CN CNB018079598A patent/CN1245963C/zh not_active Expired - Fee Related
- 2001-04-07 PT PT01949281T patent/PT1276476E/pt unknown
- 2001-04-07 EE EEP200200590A patent/EE05099B1/xx not_active IP Right Cessation
- 2001-04-07 ES ES01949281T patent/ES2266216T3/es not_active Expired - Lifetime
- 2001-04-07 BR BR0109996-5A patent/BR0109996A/pt active Pending
- 2001-04-07 AU AU2001270484A patent/AU2001270484B2/en not_active Ceased
- 2001-04-07 PL PL357827A patent/PL215235B1/pl unknown
- 2001-04-07 AT AT01949281T patent/ATE330588T1/de active
- 2001-04-07 NZ NZ521934A patent/NZ521934A/en not_active IP Right Cessation
- 2001-04-07 RS YUP-769/02A patent/RS51478B/sr unknown
- 2001-04-07 EP EP01949281A patent/EP1276476B1/de not_active Expired - Lifetime
- 2001-04-07 US US10/257,481 patent/US7208508B2/en not_active Expired - Fee Related
- 2001-04-07 DE DE50110262T patent/DE50110262D1/de not_active Expired - Lifetime
- 2001-04-07 SI SI200130616T patent/SI1276476T1/sl unknown
- 2001-04-07 AU AU7048401A patent/AU7048401A/xx active Pending
- 2001-04-07 CA CA002575059A patent/CA2575059A1/en not_active Abandoned
- 2001-04-07 JP JP2001576000A patent/JP3905386B2/ja not_active Expired - Fee Related
- 2001-04-07 ME MEP-459/08A patent/MEP45908A/xx unknown
- 2001-04-07 CZ CZ20023752A patent/CZ300549B6/cs not_active IP Right Cessation
- 2001-04-07 HU HU0300917A patent/HU228387B1/hu not_active IP Right Cessation
- 2001-04-07 DK DK01949281T patent/DK1276476T3/da active
- 2001-04-07 CA CA002404120A patent/CA2404120C/en not_active Expired - Fee Related
- 2001-04-07 SK SK1458-2002A patent/SK286075B6/sk not_active IP Right Cessation
- 2001-04-07 MX MXPA02009935A patent/MXPA02009935A/es active IP Right Grant
- 2001-04-07 KR KR1020027013688A patent/KR20020089453A/ko not_active Application Discontinuation
- 2001-04-07 TR TR2002/02326T patent/TR200202326T2/xx unknown
- 2001-04-07 WO PCT/EP2001/004034 patent/WO2001078699A2/de active IP Right Grant
- 2001-04-07 EA EA200201053A patent/EA006977B1/ru not_active IP Right Cessation
- 2001-04-07 EP EP06111485A patent/EP1666042A3/de not_active Withdrawn
- 2001-07-04 UA UA2002118949A patent/UA78679C2/uk unknown
-
2002
- 2002-09-13 BG BG107103A patent/BG65816B1/bg active Active
- 2002-10-03 IL IL152103A patent/IL152103A/en not_active IP Right Cessation
- 2002-10-10 ZA ZA200208162A patent/ZA200208162B/en unknown
- 2002-10-11 HR HRP20020815 patent/HRP20020815A2/hr not_active Application Discontinuation
- 2002-10-11 NO NO20024924A patent/NO330311B1/no not_active IP Right Cessation
-
2006
- 2006-07-07 CY CY20061100956T patent/CY1105081T1/el unknown
-
2007
- 2007-03-12 US US11/684,974 patent/US20070155679A1/en not_active Abandoned
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015557B (zh) * | 2005-12-21 | 2010-12-08 | 瑟维尔实验室 | 窦房结If电流抑制剂与血管紧张肽转化酶抑制剂的新组合以及含有它的药物组合物 |
| TWI415605B (zh) * | 2006-10-06 | 2013-11-21 | 百靈佳殷格翰維美迪加股份有限公司 | 用於預防或治療貓之全身性疾病之血管緊張素ii受體拮抗劑 |
| CN105148272A (zh) * | 2006-10-06 | 2015-12-16 | 贝林格尔·英格海姆维特梅迪卡有限公司 | 用于治疗猫全身性疾病的血管紧张素ii受体拮抗剂 |
| CN109125730A (zh) * | 2006-10-06 | 2019-01-04 | 贝林格尔·英格海姆维特梅迪卡有限公司 | 用于治疗猫全身性疾病的血管紧张素ii受体拮抗剂 |
| CN114344293A (zh) * | 2006-10-06 | 2022-04-15 | 贝林格尔·英格海姆维特梅迪卡有限公司 | 用于治疗猫全身性疾病的血管紧张素ii受体拮抗剂 |
| CN114344293B (zh) * | 2006-10-06 | 2024-04-19 | 贝林格尔·英格海姆维特梅迪卡有限公司 | 用于治疗猫全身性疾病的血管紧张素ii受体拮抗剂 |
| CN102284060A (zh) * | 2010-06-15 | 2011-12-21 | 瑟维尔实验室 | 窦房结If当前抑制剂和血管紧张素转化酶抑制剂的组合在治疗心力衰竭中的用途 |
| TWI468164B (zh) * | 2010-06-15 | 2015-01-11 | Servier Lab | 竇房結Ｉｆ電流抑制劑及血管收縮素轉化酶抑制劑之結合用於治療心衰竭之用途 |
| CN103781468A (zh) * | 2011-08-12 | 2014-05-07 | 勃林格殷格翰动物保健有限公司 | 治疗及预防猫科动物心脏衰竭的方法中所用的起搏电流(If)抑制剂 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1245963C (zh) | 包括心动徐缓剂的药物组合物及其用途 | |
| US9655852B2 (en) | Tablets containing a 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound | |
| RU2184563C2 (ru) | Твердая лекарственная форма, содержащая рамиприл в качестве ингибитора ангиотензинконвертирующего фермента, и соединение дигидропиридина | |
| TWI404534B (zh) | 包含氨氯地平（ａｍｌｏｄｉｐｉｎｅ）及洛沙坦（ｌｏｓａｒｔａｎ）且具有經改良穩定性之固體藥學組成物 | |
| CN108042808A (zh) | 用于治疗中枢系统疾病的包含依匹哌唑或其盐和第二种药物的组合 | |
| TW200948358A (en) | Dissolution improved pharmaceutical composition comprising olmesartan medoxomil | |
| KR101907881B1 (ko) | 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형 | |
| CZ20002939A3 (cs) | Farmaceutické kombinace obsahující tramadol | |
| TW201338772A (zh) | 藥學組合物 | |
| KR101414814B1 (ko) | 염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법 | |
| KR102369607B1 (ko) | 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물 | |
| AU2013247291A1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| CN102397278A (zh) | 一种抗高血压药物组合物 | |
| CN1270711C (zh) | 氨氯地平、厄贝沙坦复方制剂 | |
| CN102406616A (zh) | 一种联合蒙脱石的普萘洛尔缓释干混悬剂、其制备方法和用于其中的钠基蒙脱石的制备方法 | |
| CN114557992A (zh) | 一种复方药物组合物在制备治疗间质性肺炎药物中的应用 | |
| RU2145222C1 (ru) | Фармацевтическая композиция, обладающая антигистаминным действием | |
| TW200303203A (en) | N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine and use thereof as medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1053979 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060322 Termination date: 20160407 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |